Bausch Health Companies vs Teva Pharmaceutical Industries
BHC and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BHC and TEVA compare
Teva Pharmaceutical Industries is the larger company, worth 16 times as much as Bausch Health Companies ($48.3B against $3.1B).
Bausch Health Companies grew revenue faster over the last twelve months (10.1% versus −15.2% for Teva Pharmaceutical Industries).
Teva Pharmaceutical Industries keeps more of each dollar of sales as profit, with a net margin of 5.0% compared with −10.1% at Bausch Health Companies.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BHC | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $3.1B | $48.3B |
| Share price | $8.20 | $41.47 |
| Change, 1 year | 39.0% | 110% |
| Change, 5 years | −70.7% | 354% |
| Beta (5Y) | 1.05 | 0.99 |
| Employees | 20K | 34K |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 69.1× |
| P/S | 0.3× (better) | 3.4× |
| P/B | – | 6.2× |
| EV/EBITDA | 11.2× (better) | 19.0× |
| P/FCF | 2.1× (better) | 35.8× |
| FCF yield | 46.7% (better) | 2.8% |
| Fair value | $24.85 | $18.65 |
| Margin of safety | 67.0% (better) | −122% |
| Growth | ||
| Revenue growth (TTM) | 10.1% (better) | −15.2% |
| Revenue growth, 5Y average | 5.0% (better) | 0.71% |
| Net income growth (TTM) | −1220% | – |
| EPS growth (TTM) | −1238% | – |
| Profitability | ||
| Gross margin | – | 64.4% |
| Operating margin | 8.1% | 11.4% (better) |
| Net margin | −10.1% | 5.0% (better) |
| FCF margin | 13.2% (better) | 9.6% |
| Return on equity | – | 9.7% |
| Return on invested capital | 3.8% | 23.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.58 |
| Net debt / EBITDA | 9.20 | 0.33 (better) |
| Interest coverage | 0.5× | – |
| Current ratio | 1.44 (better) | 0.88 |
| Altman Z-score | 0.11 | 0.84 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 63.4% | – |
| Held by insiders | 31.5% | 0.43% |
| Insider net buying, 12 months | $15.1M (better) | −$113M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.3% | 2.6% |
Go deeper
- BHC stock overview
- BHC income statement
- BHC valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.